Kim N. Chi
金·池
MD, FRCPC
Professor of Medicine; Vice President, Research, BC Cancer医学教授；不列颠哥伦比亚癌症中心研究副总裁
👥Biography 个人简介
Kim Chi is a leading Canadian prostate cancer clinician-scientist at BC Cancer. He led the PROfound trial establishing olaparib for BRCA1/2- and HRR-mutated mCRPC, and has contributed extensively to biomarker-driven therapy and androgen receptor pathway targeting in advanced prostate cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PARP Inhibition in HRR-Mutated mCRPC
Led the PROfound phase III trial showing olaparib improved radiographic progression-free survival in mCRPC patients with homologous recombination repair gene alterations, leading to FDA approval.
Representative Works 代表性著作
Olaparib for Metastatic Castration-Resistant Prostate Cancer (PROfound)
New England Journal of Medicine (2020)
Landmark trial demonstrating olaparib's efficacy in BRCA1/2- or ATM-mutated mCRPC, establishing precision oncology in prostate cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 金·池 的研究动态
Follow Kim N. Chi's research updates
留下邮箱，当我们发布与 Kim N. Chi（BC Cancer, University of British Columbia）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment